Fair Value Calculator Fair Value Calculator
EN DE

Avant Brands Inc (AVNT) Fair Value & Analysis

Healthcare · CA · Market cap C$9.2M

AB Avant Brands Inc AVNT · TO
PriceC$0.5500
Fair ValueC$0.6242
Upside+13.5%
Quality32/100
Watch Avant Brands Inc for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range C$0.3941 – C$0.8542

Fair value as of: Jul 14, 2026

From 7 valuation models · updated today

Share price −14.1% over the past month.

Price vs Fair Value (12 months)

C$1.05 C$0.5000 Fair Value C$0.6242 Jul 2025 Jul 2026

12‑month range C$0.5000 – C$1.05 · fair‑value band C$0.3941 – C$0.8542 · the C$0.5500 price screens below the C$0.6242 fair value. As of Jul 14, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Avant Brands Inc (AVNT) currently trades at C$0.5500, while our model-based Fair Value estimate is C$0.6242 — implying the stock looks roughly 13.5% undervalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, Avant Brands Inc generated revenue of C$34.4M at a net margin of -36.1%. Revenue declined 17.9% year over year. It earns a return on equity of -46.4%. Net debt stands at C$13.8M. Fundamentals as of Jul 14, 2026

Our scenario range runs from C$0.3941 (bear case) to C$0.8542 (bull case); at C$0.5500, the current price sits within that range. The share trades about 49% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside — at 13%, AVNT screens cheaper than that median.

Key figures & financial health

Revenue (TTM) C$34.4M
Revenue growth (YoY) -17.9%
Net margin -36.1%
Return on equity -46.4%
Free cash flow C$5.7M FY2025
Operating margin -42.6%
More key figures
EPS (TTM) C$-1.09
EPS growth (YoY) -59.6%
Net debt C$13.8M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.

About the company

Avant Brands Inc. cultivates, produces, markets, and sells cannabis products in Canada. The company offers recreational cannabis products under the BLK MKT, Tenzo, Cognoscente, Treehugger, Pristine, and Flowr brands. It also provides medical cannabis products under the GreenTec brand. The company distributes cannabis through medical and recreational sales channels, as well as an e-commerce website. It also exports its products through the wholesale channel. The company was formerly known as GTEC Holdings Ltd. and changed its name to Avant Brands Inc. in July 2021. Avant Brands Inc. is headquartered in Kelowna, Canada.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Avant Brands Inc reported revenue of C$35.9M in FY2025 versus C$9.5M in FY2021, a compound +39.4%/yr. Reported net income was −C$9.9M in FY2025.

Revenue +39.4%/yr
FY21 C$9.5M
FY22 C$20.1M
FY23 C$26.3M
FY24 C$35.8M
FY25 C$35.9M
Net income
FY21 −C$11.2M
FY22 −C$7.5M
FY23 −C$5.1M
FY24 −C$22.6M
FY25 −C$9.9M

Is AVNT fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Avant Brands Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVNT.TO

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 1276 HK$57.85 HK$29.84 -48%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,786 ₹991.46 -44%
Zoetis Inc Z1TS34 R$26.19 R$26.01 -1%
Hansoh Pharmaceutical Group 3692 HK$29.30 HK$23.90 -18%
Divi's Laboratories Limited DIVISLAB ₹6,623 ₹1,461 -78%
PharmaEssentia Corporation 6446 934.00 TWD 365.87 TWD -61%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,421 ₹1,504 -66%
Cipla Limited CIPLA ₹1,416 ₹1,466 +4%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,089 ₹841.98 -23%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,291 ₹1,053 -18%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Avant Brands Inc (AVNT) undervalued?
As of Jul 14, 2026, our model estimates a fair value of C$0.6242 versus a price of C$0.5500 — about +13% (undervalued). Model-based estimate, not financial advice.
What is the fair value of AVNT?
Our model-based fair value for Avant Brands Inc is C$0.6242 (as of Jul 14, 2026), built from audited fundamentals. The current price is C$0.5500.
What is the quality score of AVNT?
Avant Brands Inc has a Quality Score of 32/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Avant Brands Inc (AVNT)?
Avant Brands Inc reported trailing-twelve-month revenue of about C$34.4M (latest available figure, as of Jul 14, 2026).
What is the net profit margin of AVNT?
The net profit margin of Avant Brands Inc is about -36.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

14 days Pro free · no card

Unlock the full Avant Brands Inc analysis — and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.